Journal of Analytical Toxicology 2008-05-01

Novel automated extraction method for quantitative analysis of urinary 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH).

Shanlin Fu, John Lewis

Index: J. Anal. Toxicol. 32(4) , 292-7, (2008)

Full Text: HTML

Abstract

An automated extraction method for extracting the major urinary metabolite of cannabis, 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) was developed on the four-probe Gilson ASPEC XL4trade mark solid-phase extraction (SPE) system. The method works on liquid-liquid extraction principles but does not require the use of SPE cartridges. The limits of detection and quantitation and the upper limit of linearity (ULOL) of the developed method were found to be 1, 2, and 1,500 ng/mL, respectively. There was no detectable carry over after 10,000 ng/mL analyte. For a batch of 76 samples, the process uses less than 100 mL methanol, 450 mL extracting solvent hexane/ethyl acetate (5:1, v/v) and 1 L rinsing solvent, 30% methanol in water. The automated extraction process takes 5 h to complete. Precision and accuracy of the method are comparable to both manual liquid-liquid extraction and automated SPE methods. The method has proven to be a simple, speedy, and economical alternative to the currently popular automated SPE method for the quantitative analysis of urinary THC-COOH.


Related Compounds

  • Δ9-tetrahydrocanna...

Related Articles:

[Simultaneous determination of delta-9-tetrahydrocannabinol cannabidiol and cannabinol in edible oil using ultra performance liquid chromatography-tandem mass spectrometry].

2010-11-01

[Se Pu 28(11) , 1015-9, (2010)]

Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

2009-11-01

[Drug Alcohol Depend. 105(1-2) , 24-32, (2009)]

Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

2009-10-01

[J. Anal. Toxicol. 33(8) , 469-77, (2009)]

Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial.

2012-06-01

[Addiction 107(6) , 1123-31, (2012)]

[Interpretation of blood analysis data found after passive exposure to cannabis].

2010-01-01

[Arch. Kriminol. 225(3-4) , 90-8, (2010)]

More Articles...